宫颈神经内分泌癌的预后因素

Prognostic factors of neuroendocrine carcinoma of the cervix:a retrospective study

目的探讨影响宫颈神经内分泌癌预后的因素。方法回顾性分析2009年12月~2020年7月收治于广州医科大学附属肿瘤医院的30例宫颈神经内分泌癌患者的临床病理资料、治疗方案,随访截止至2021年3月31日,对数据进行单因素和多因素生存分析。结果中位随访时间为43(9~135)月,中位无进展生存时间和总生存时间分别为16(1~102)月、19(3~102)月,中位年龄为44.5岁(21~65岁)。截至随访日期,13例(43.3%)患者存活。单因素分析表明,手术(P<0.001)、化疗(P=0.018)、盆腔淋巴结转移(P=0.006)以及分期(P=0.014)对无进展生存时间有影响。手术和盆腔淋巴结转移对总生存时间具有影响(P<0.001,P=0.033)。Cox回归模型多因素分析表明,手术及化疗是影响无进展生存时间的两个独立因素(P=0.002,P=0.005),手术是影响总生存时间的唯一独立因素(P=0.002)。年龄、分期、肿瘤大小、病理类型、盆腔淋巴结转移、化疗疗程及放疗均不是影响预后的独立因素。结论宫颈神经内分泌癌的预后与是否行手术和化疗密切相关,适合手术的患者应行手术治疗,化疗作为辅助治疗可使患者生存受益,即使早期患者也建议联合化疗。

Objective To analyze prognostic factors of patients with neuroendocrine carcinoma of the cervix(NECC).Methods Thirty patients with NECC between December 2009 and July 2020 in Affiliated Cancer Hospital&Institute of Guangzhou Medical University were retrospectively reviewed.Clinicopathologic characteristics and primary treatments were reviewed.The end of the follow-up time was March 31st,2021.The factors were analyzed using Kaplan-Meier and Cox regression methods.Results With a median follow-up of 43 months(9-135 months),13(43.3%)patients were alive.The median PFS was 16 months(1-102 months),median OS was 19 months(3-102 months).The median age was 44.5 years(21-65 years).Univariate analysis showed that surgery(P<0.001),chemotherapy(P=0.018),pelvic lymph node metastasis(P=0.006)and stage(P=0.014)were significant prognostic factors for PFS.For OS,only surgery and pelvic lymph node metastasis were significant prognostic factors(P<0.001,P=0.033).In multivariate analyses,surgeryand chemotherapy were independent prognostic factors for PFS(P=0.002,P=0.005).Surgery was the sole independent prognostic factor for OS(P=0.002).Age,stage,tumor size,histology,pelvic lymph node metastasis,cycles of chemotherapy and radiotherapy were not independent prognostic factors.Conclusion The prognosis of NECC is closely related with surgery and chemotherapy.Patients with indication for surgery should be treated with it.Chemotherapy was advised as adjuvant therapy even in early stage.